Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Veru Inc (VERU)

Veru Inc (VERU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 471,377
  • Shares Outstanding, K 80,030
  • Annual Sales, $ 61,260 K
  • Annual Income, $ 7,390 K
  • 60-Month Beta 0.45
  • Price/Sales 7.69
  • Price/Cash Flow N/A
  • Price/Book 3.09
Trade VERU with:

Options Overview Details

View History
  • Implied Volatility 107.05% ( +12.26%)
  • Historical Volatility 83.45%
  • IV Percentile 79%
  • IV Rank 25.25%
  • IV High 213.17% on 02/11/21
  • IV Low 71.21% on 08/18/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 371
  • Volume Avg (30-Day) 1,404
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 29,834
  • Open Int (30-Day) 38,217

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.23
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -550.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.11 +15.26%
on 01/10/22
6.66 -11.56%
on 01/11/22
-0.05 (-0.84%)
since 12/14/21
3-Month
5.11 +15.26%
on 01/10/22
10.00 -41.10%
on 11/15/21
-2.85 (-32.61%)
since 10/14/21
52-Week
5.11 +15.26%
on 01/10/22
24.57 -76.03%
on 02/09/21
-3.77 (-39.03%)
since 01/14/21

Most Recent Stories

More News
Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

AZN : 58.85 (+1.29%)
LLY : 244.12 (-2.22%)
ANAB : 33.74 (+3.09%)
VERU : 5.89 (unch)
Promising Developments in Breast Cancer Treatments Ahead in 2022

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – January 12, 2022 – USA News Group  –  So far in 2022, there have already been some impressive developments in the battle...

ONCY : 1.6200 (+5.19%)
ONC.TO : 1.98 (-1.98%)
ILMN : 405.14 (+1.41%)
ZLAB : 49.78 (-3.60%)
MRUS : 28.46 (+3.00%)
VERU : 5.89 (unch)
Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022

VANCOUVER – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female...

ONCY : 1.6200 (+5.19%)
ONC.TO : 1.98 (-1.98%)
ILMN : 405.14 (+1.41%)
ZLAB : 49.78 (-3.60%)
MRUS : 28.46 (+3.00%)
VERU : 5.89 (unch)
Why Veru Stock Triumphed on Tuesday

The company wins Fast Track designation for a top pipeline program.

VERU : 5.89 (unch)
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates

OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

OGI : 1.6400 (-1.20%)
VERU : 5.89 (unch)
Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for...

VERU : 5.89 (unch)
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022-- ...

VERU : 5.89 (unch)
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for...

VERU : 5.89 (unch)
Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VERU : 5.89 (unch)
NEOG : 38.92 (-0.08%)
Veru Reports Record Fiscal 2021 Full-Year Financial Results

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin...

VERU : 5.89 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered...

See More

Key Turning Points

3rd Resistance Point 6.28
2nd Resistance Point 6.12
1st Resistance Point 6.00
Last Price 5.89
1st Support Level 5.72
2nd Support Level 5.56
3rd Support Level 5.44

See More

52-Week High 24.57
Fibonacci 61.8% 17.14
Fibonacci 50% 14.84
Fibonacci 38.2% 12.54
Last Price 5.89
52-Week Low 5.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar